WO2022059027A1 - Composition topique de luliconazole - Google Patents

Composition topique de luliconazole Download PDF

Info

Publication number
WO2022059027A1
WO2022059027A1 PCT/IN2021/050916 IN2021050916W WO2022059027A1 WO 2022059027 A1 WO2022059027 A1 WO 2022059027A1 IN 2021050916 W IN2021050916 W IN 2021050916W WO 2022059027 A1 WO2022059027 A1 WO 2022059027A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
luliconazole
sodium
disodium
shampoo
Prior art date
Application number
PCT/IN2021/050916
Other languages
English (en)
Inventor
Ulhas Dhuppad
Akhilesh Sharma
Babasaheb Aware
Viraj SHAH
Chirag TELI
Supriya AMBEDKAR
Jitendra Jaikumar GANGWAL
Original Assignee
Alkem Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Limited filed Critical Alkem Laboratories Limited
Publication of WO2022059027A1 publication Critical patent/WO2022059027A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00—Fungicides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to a topical, foamable composition
  • a topical, foamable composition comprising Luliconazole, and pharmaceutically acceptable excipients selected from group consisting of surfactant, preservative, chelating agent, viscosifier, suspending agent, conditioner, emollient, pH adjuster and mixture thereof.
  • the said composition has various advantages such as low irritant to the skin or eyes, produces excellent creamy foam, possesses a superior hair conditioning effect, and imparts an outstanding moisture feeling to the skin. It also causes lesser hair discoloration when compared to other antifungal topical composition.
  • the present invention relates to topical compositions such as body and/or hair cleansing products, in particular but not limited to shampoo or lotion, comprising of one or more antifungal(s) such as luliconazole indicated for the topical treatment and prophylaxis of conditions in which the Malassezia spp. are involved. It is also used to reduce relapse rates and maintain remissions for Seborrheic dermatitis.
  • topical compositions such as body and/or hair cleansing products, in particular but not limited to shampoo or lotion, comprising of one or more antifungal(s) such as luliconazole indicated for the topical treatment and prophylaxis of conditions in which the Malassezia spp. are involved. It is also used to reduce relapse rates and maintain remissions for Seborrheic dermatitis.
  • Fungal infections are a major health problem and an important cause of morbidity. Fungal infections may be categorized as superficial or invasive. Superficial fungal infections affect as many as 20%-25% of the world’s population and are associated with interference with daily activities, poor quality of life, and health care expenditure. Invasive fungal infections are usually encountered in the presence of one or more predisposing factors, such as in critically ill or immunocompromised patients and those with indwelling catheters and devices, and deep or systemic fungal infections are an important cause of hospitalization and mortality. Superficial fungal infections can be attributed to Dermatophytes, Candida, and Malassezia spp. infection. The genus Malassezia includes multiple lipid-dependent species, the most common being M.
  • An antifungal agent is a drug that selectively eliminates fungal pathogens from a host with minimal toxicity to the host.
  • Commonly used antifungals includes but not limited to polyenes, azoles, allylamine and morpholines.
  • Topical antifungal therapy is preferred over oral antifungals due to various advantages like lack of systemic side effects and complications due to limited systemic absorption, very low incidence of drug interactions, ease of use, comparatively low cost of therapy, and additional benefit of antiinflammatory activity of several topical antifungals including azoles and allylamines.
  • Topical antifungals are products that treat fungal infections and which are applied directly to the skin, nails, or hair; vaginally; or inside the mouth. They are available as creams, gels, lotions, nail lacquers, ointments, powders, shampoos, sprays, and tinctures.
  • Azoles are synthetic and semi-synthetic compounds. Commonly used azole are ketoconazole, teraconazole, itraconazole, fluconazole, voriconazole
  • luliconazole is the preferred fungicidal agent the following can also be used as fungicidal agent in combination with or in place of luliconazole: ketoconazole, amphotericin B, butaconazole, amorolfine, anidulafungin, butenafine, butoconazole, caspofungin, ciclopirox, clotrimazole, dapsone, econazole, fluconazole, flucytosine, gentian violet, griseofulvin, haloprogin, itraconazole, micafungin, miconazole, naftifine, nystatin, oxiconazole, pimaricin, posaconazole, ravoconazole, rimocidin, silver sulf
  • ketoconazole shampoos which are marketed in a 2% formulation and which show a beneficial effect in seborrheic-dermatitis after topical application.
  • U.S. Pat. No. 5456851 discloses ketoconazole shampoos that exhibit better cosmetic attributes such as lathering and conditioning, and are acceptably stable to degradation so that they can be formulated to contain less than 2 % active ingredient.
  • WO 1996029045 discloses combinations of such a cytotoxic agent and an antifungal agent for the treatment of seborrheic dermatitis of the scalp; specifically disclosed is the combined use of an unidentified composition comprising 1.8 % coal tar and an unidentified solution comprising 2 % ketoconazole.
  • WO 2019070221 discloses topical pharmaceutical compositions, comprising luliconazole or pharmaceutically acceptable salts, polymorphs, stereoisomers, solvates, hydrates or esters thereof and at least one pharmaceutically acceptable excipient.
  • WO 2017203456 discloses stable topical compositions comprising luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol. The compositions are free of an aliphatic alcohol and a ketone.
  • Ketoconazole shampoo known to possess severe adverse effects like hypersensitivity reactions, including anaphylaxis, angioedema, irritation to mucous membranes of eyes and scalp, hair discoloration, it also causes abnormal hair texture, removal of the curl from permanently waved hair, itching, alopecia, rashes and urticaria, skin burning sensation, skin irritation, dry skin, and application site reactions.
  • commonly used antifungal shampoo or lotion preparation contains cocamide diethanolamide, and Sodium cocoyl sarcosinate/Sodium lauryl sarcosinate which having potential undesired side effects.
  • Small doses of Cocamide diethanolamide can cause itchiness and rash. In large doses, it can be a carcinogen.
  • Sodium cocoyl sarcosinate is harmful for the DNA in mammal cells. It also shows very high acute toxicity towards respiratory system.
  • the present invention provides a topical composition
  • a topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients.
  • the present invention relates to topical composition
  • topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients selected from the group consisting of surfactants, preservative, chelating agent, viscosifier, suspending agent, conditioner, emollient and mixture thereof.
  • the present invention relates to stable composition for topical application to a human comprising about 0.05% to about 10% w/w luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients selected from the group consisting of surfactants, preservative, chelating agent, viscosifier, suspending agent, conditioner, emollient and mixture thereof wherein the composition is not free of sodium lauryl ether sulfate.
  • the present invention relates to topical composition
  • the present invention relates to topical composition
  • a luliconazole for topical application wherein the dosage form for topical application is selected from the group consisting of shampoo, lotion, gel, cream or ointment.
  • compositions for topical application to a human in the form of shampoo or lotion comprising about 0.5 % w/w to about 5% w/w luliconazole or its derivative wherein the composition does not contain any additional active agents such as salicylic acid or zinc pyrithione.
  • composition comprising luliconazole which is substantially free of Cocamide diethanolamide.
  • composition comprising luliconazole which is substantially free of sodium cocoyl sarcosinate.
  • composition comprising luliconazole which is substantially free of natural oil and surfactants such as parabens and azolinones.
  • a topical composition comprising luliconazole and pharmaceutically acceptable excipients such as cocamidopropyl betaine, bis-aminopropyl dimethicone and polyethylene glycol ether for beneficial effects.
  • Cocamidopropyl Betaine used as conditioning agent has skin hydrating properties and prevent skin from drying out;
  • Bis- Aminopropyl Dimethicone has strong polarity, can interact with hydroxyl and carboxyl on hair surface, brings very good orientation and absorption property, helps in formation of a smooth and solid film on the hair and polyethylene glycol ether which is compatible with non-ionic, anionic, amphoteric, and cationic surfactants.
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 0.5 % w/w to about 5 % w/w of luliconazole; b) about 5 % w/w to about 30 % w/w of surfactant; c) about 0.5% w/w to about 3.5 % w/w of conditioner; and d) pharmaceutically acceptable excipients selected from the group consisting of preservative, chelating agent, suspending agent, viscosifier, emollient, pH adjuster, perfume, and mixture thereof. wherein all these percentages being expressed relative to the total weight of the composition.
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 0.5 % w/w to about 5 % w/w of luliconazole; b) about 5 % w/w to about 25 % w/w of anionic surfactant selected from alkyl sulfate and alkyl ether sulfate salts such as sodium lauryl ether sulfate , disodium laureth sulfosuccinate, ammonium laureth sulfate, sodium myreth sulfate, sodium methyl 2- sulfolaurate, disodium 2-sulfolaurate, sodium C14-16 olefin sulfonate, and sodium lauroyl methyl isethionate, sodium lauryl sulfate and mixture thereof; c) about 0.25 % w/w to about 3 % w/w of non-
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 0.5 to about 5 % by weight of luliconazole along with surfactants and conditioner; and b) pharmaceutically acceptable excipients includes but not limited to preservatives such as Imidurea (Imidazolidinyl urea), benzoates (such as sodium benzoate, benzoic acid), nitrites (such as sodium nitrite), sulphites (such as sulphur dioxide) or sorbates (such as sodium sorbate, potassium sorbate), chelating agent such as diiospropyl oxalate, disodium EDTA, disodium EDTA-copper, EDTA, diethylene-triamine-pentaacetic acid (DTPA), iminodisuccinic acid (IDS), Ethylenediamine disuccinic acid (EDDS); emollients are choosen from petrol
  • preservatives
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 2 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of Polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53 ; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of diso
  • a topical compostion of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 1 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of Polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53 ; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 4 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of Polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53 ; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of diso
  • compositions for topical application the composition being in the form of suspension comprising a) about 2 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of disodium EDTA;
  • compositions for topical application comprising a) about 1 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of disodium EDTA;
  • compositions for topical application comprising a) about 4 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of disodium EDTA;
  • the pharmaceutical compositions comprising luliconazole having a dso of about 11 to about 20 pm, preferably from about 12 to about 16 pm. In another aspect, the pharmaceutical compositions comprising luliconazole having a dw from about 21 to about 50 pm, preferably from about 22 to about 30 pm. In another aspect, the pharmaceutical compositions comprising luliconazole having a dio from about 1 to about 10 pm, preferably from about 5 to about 10 pm.
  • the present invention relates to method of treating dandruff or seborrheic dermatitis , fungal infections associated with Malassezia spp. like pityriasis versicolor as well as dermatophytic infections like tinea capitis, tinea barbae of hairy areas for washing & treating the skin, hair or the scalp by the application of topical shampoo or lotion composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients.
  • the present invention relates to topical composition
  • topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients for the treatment of dandruff or seborrheic dermatitis , fungal infections associated with Malassezia spp. like pityriasis versicolor as well as dermatophytic infections like tinea capitis, tinea barbae of hairy areas for washing & treating the skin, hair or the scalp.
  • the present invention relates to use of topical composition
  • topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients for the treatment of dandruff or seborrheic dermatitis , fungal infections associated with Malassezia spp. like pityriasis versicolor as well as dermatophytic infections like tinea capitis, tinea barbae of hairy areas for washing & treating the skin, hair or the scalp.
  • a luliconazole shampoo or lotion composition wherein the extent of wrinkling and sloughing (mild) as well as incidences i.e. irritant properties of said shampoo or lotion were comparable with that of the marketed shampoo or lotion composition.
  • a luliconazole shampoo or lotion composition wherein the said shampoo is comparable with marketed shampoo or lotion in terms of skin irritation potential.
  • a luliconazole shampoo or lotion composition wherein the said shampoo or lotion have minimally irritating eye irritation potential and is comparable with marketed shampoo or lotion.
  • the invention is directed to methods of using such composition for the treatment of dandruff, Malassezia infections like Pityriasis versicolor, fungal infections like tinea barbae, tinea capitis, etc It also reduces relapse rates and maintains remissions for Seborrheic dermatitis.
  • the invention is directed to a process for preparation of aqueous shampoo or lotion of Luliconazole or one or more of its salts, comprising the steps of: 1. Disodium laureth sulfosuccinate, Laureth-3, purified water were taken and luliconazole API was added in it. Further it was stirred to get uniform dispersion. 2. Purified water was taken and acrylic polymer such as carbopol silk 100 was added in it. Further it was stirred to get uniform dispersion. 3. Sodium carboxymethylcellulose was added to step-2 and stirred to get uniform dispersion. 4. Step-01 was added to step-03 and stirred to get uniform dispersion. 5.
  • Cocoamidopropyl betaine, dimethicone and aminopropyldimethicone, polyquarternium-53, disodium cocoampho diacetate, PEG-7 glyceryl cocoate were added one after another to step-04 and stirred to get uniform dispersion. 6.
  • purified water was taken and disodium edetate, imidurea dissolved under stirring to get uniform solution.
  • Step-05 was added to step-04 and stirred to get uniform dispersion.
  • Perfume was added to step-06 and stirred to get uniform dispersion.9.
  • Sodium laureth sulfate paste 70% was added to step-07 and stirred to get uniform dispersion.10. pH of step-09 was adjusted using 3M sodium hydroxide solution to 6-7.5 11. Weight of batch was made by using purified water. Detailed description of the drawing:
  • Figure 1 and 2 is a bar graph depicting hair sensory evaluation of luliconazole anti -dandruff shampoo composition as described in example 3 with respect to marketed anti-dandruff shampoo sample and control sample.
  • Figure 3 and 4 shows cationic polymer deposition evaluation by Red 80 Dye method of luliconazole anti -dandruff shampoo composition as described in example 3 with respect to marketed anti-dandruff shampoo sample and control sample.
  • Luliconazole also known as NND-502, is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture.
  • Luliconazole although belonging to the azole group, has strong fungicidal activity against Trichophyton spp., similar to that of terbinafine.
  • the strong clinical antifungal activity of luliconazole is possibly attributable to a combination of strong in vitro antifungal activity and favorable pharmacokinetic properties in the skin.
  • Superficial fungal infections can be attributed to dermatophytes, Candida, and Malassezia spp. infections. Dermatophytes are aerobic fungi and the most common offenders in superficial fungal infections. Physiologically, these dermatophytes have the ability to digest keratin for growth and replicate in the superficial layers of the epidermis. Consequently, in clinical practice, the body parts most affected by dermatophytic infection are those rich in keratin, such as the hair, skin, and nails.
  • Candidiasis is an infection caused by yeasts of the genus Candida. Superficial infections of the mucous membranes and skin are most frequent, but Candida can also cause deep invasive disease, including septicemia, endocarditis, and meningitis.
  • Malassezia includes multiple lipid-dependent species, the most common being M. sympodialis, M. globosa, M. restricta, M. slooffiae, M. furfur, and M. obtus. Colonization by these species is especially dense in the scalp, upper trunk, and flexures, areas rich in sebaceous glands and their secretions. Malassezia spp. are the main cause of pityriasis versicolor and Malassezia folliculitis, and are also believed to have a role in seborrheic dermatitis as well as dandruff.
  • Luliconazole 1% cream was approved in Japan in 2005 for the treatment of tinea infections, followed by approval in November 2013 by the US Food and Drug Administration for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms T. rubrum and E. floccosum, in patients 18 years of age and older. It is indicated for once-daily application for one week in tinea corporis/cruris and for 2 weeks in tinea pedis.
  • the present invention provides a topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients with lowest possible incidence of side effects, like absence of symptoms such as irritation, pruritus and scaling; improved cosmetic acceptability, in particular, good cleansing properties, overall conditioning (wet and dry combing properties), absence of odour or stench.
  • the invention is devoid of natural oil and surfactants like parabens, azolinones, thus potential side effects associated with them like; hormonal imbalance, lung toxicity, allergic reactions and possible neurotoxicity can be avoided.
  • the present invention provides pharmaceutical composition characterized in that the composition comprises therapeutically effective amount of luliconazole in the range of about 0.05 % to about 10 % w/w of the total composition.
  • the composition comprises therapeutically effective amount of luliconazole in the range of about 0.05 % to about 10 % w/w of the total composition.
  • the composition comprises therapeutically effective amount of luliconazole in the range of about 0.05 % to about 10 % w/w of the total composition.
  • the composition comprises therapeutically effective amount of luliconazole in the range of about 0.05 % to about 10 % w/w of the total composition.
  • topical composition of luliconazole can be applied either at least once or twice in a week.
  • the present invention relates to topical composition
  • topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients selected from the group consisting of surfactants, preservative, chelating agent, viscofier, suspending agent, conditioner, emollient, pH adjuster and mixture thereof.
  • the instant topical composition of luliconazole and pharmaceutically acceptable surface active agents include but not limited to anionic surfactant, non-ionic surfactant, amphoteric surfactant and cationic surfactant.
  • Anionic surfactants selected from but not limited to alkyl sulfate and alkyl ether sulfate salts such as sodium lauryl ether sulfate (SLES), ammonium laureth sulfate, sodium lauryl sulfate, disodium lauryl sulfosuccinate and ammonium lauryl sulfate, sodium myreth sulfate, sodium methyl 2- sulfolaurate, disodium 2-sulfolaurate, sodium Cl 4- 16 olefin sulfonate, and sodium lauroyl methyl isethionate or mixture thereof.
  • alkyl sulfate and alkyl ether sulfate salts such as sodium lauryl ether sulfate (SLES), ammonium laureth sulfate, sodium lauryl sulfate, disodium lauryl sulfosuccinate and ammonium lauryl sulf
  • Non-ionic surfactants are usually mild and usually used as emulsifiers, conditioning ingredients, solubilizing agents, foam stabilizers etc. These include polyoxyethers of lauryl alcohol such as 2- (Dodecyloxy) ethanol (Laureth-1), 2-[2-(Dodecyloxy) ethoxy] ethanol (Laureth- 2), Polyethylene glycol ether of lauryl alcohol (Laureth-3; 2-[2-[2-(dodecyloxy) ethoxy] ethoxy] ethanol), Alcohols, Cl 2- 14, ethoxylated (Laureth-4), coco glucosides, cocamidopropylamine oxide, and stearyl alcohol; coco glucosides, cocamidopropylamine oxide, stearyl alcohol etc.
  • lauryl alcohol such as 2- (Dodecyloxy) ethanol (Laureth-1), 2-[2-(Dodecyloxy) ethoxy] ethanol (Laureth- 2), Polyethylene glycol ether of lau
  • Amphoteric surfactants selected from but not limited to Betaines and amine oxides.
  • Preferred amphoteric surfactants include sodium laurimino dipropionate (MirataineTM H2C-HA), sodium cocoampho propionate (MiranolTM C2M-SF Cone.), cocamidopropyl betaine (MirataineTM CB), cocoamidopropyl hydroxysultaine (MirataineTM CBS), and MiranolTM JS Cone, (sodium caprylampho hydroxypropyl sultaine).
  • the cationic surfactants function by adsorbing or absorbing to the hair shaft and modifying texture and appearance. They are mild and generally considered nontoxic.
  • Cationic surfactants include but not limited to polyquaternium-7, C8-10 alkyl hydroxy ethyl dimethylammonium chloride or C8- 10 alkylamidodimethyl propylamine, alkyldimethyl amine oxides.
  • any of the above surface active agents may be used.
  • Preferred is a mixture of anionic, non-ionic and amphoteric surfactants.
  • the present invention relates to pharmaceutical composition
  • pharmaceutical composition comprising surfactants in the range of about 0.01 %w/w to about 50% w/w of the total composition.
  • surfactants in the range of about 0.01 %w/w to about 50% w/w of the total composition.
  • a conditioner is a substance or process that improves the quality of another material.
  • the present invention provides pharmaceutical composition characterized in that the composition further comprises a conditioning agent.
  • conditioning substances include but not limited to cetyltrimethyl ammonium chloride, behentrimonium or propyltrimonium, stearamidopropyl dimethylamine hydrolyzed silk, animal protein, glycerin, dimethicone and its derivatives like dimethicone and aminopropyldimethicone (such as KF 8020), simethicone, sodium caprylampho hydroxypropyl sultaine (such as MiranolTM JS Cone.), sodium cocoampho propionate (such as MiranolTM C2M-SF Cone), disodium cocoampho diacetate (such as Miranol C2M), polyvinylpyrrolidone, propylene glycol, certain polymers like ampholytic terpolymer and or its derivatives, Polyquaternium-53 (such as Merquat 2003
  • the present invention relates to pharmaceutical composition
  • pharmaceutical composition comprising conditioner in the range of about 0.05 % w/w to about 5% w/w of the total composition.
  • conditioner in the range of about 0.1 % w/w to about 5 %w/w, more preferably in the range of about 0.5% w/w to about 3.5% w/w, more preferably in the range of about 0.8 % w/w to about 3% w/w of the total composition.
  • a preservative is a natural or synthetic chemical that is added to the composition to prevent decomposition by microbial growth or by undesirable chemical changes.
  • Preservatives can be selected from but not limited to antimicrobial agents, antioxidants or chelating agents.
  • Commonly used preservatives includes but not limited to benzoates (such as sodium benzoate, benzoic acid), nitrites (such as sodium nitrite), sulphites (such as sulphur dioxide) or sorbates (such as sodium sorbate, potassium sorbate).
  • Imidurea is used as an antimicrobial agent and preservative in cosmetics and toiletries.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising preservatives in the range of about 0.005% w/w to about 5 % w/w of the total composition.
  • preservatives in the range of about 0.008% w/w to about 3 % w/w, more preferably in the range of about 0.01% w/w to about 2 % w/w, more preferably in the range of about 0.01% w/w to about- 1% w/w, more preferably about 0.15 w/w of the total composition.
  • Chelating agents are used in small amounts to react with metal ions present in hair care products or in the water, in order to improve stability or performance of the product. It provides protection against harmful metal-catalyzed reactions in the composition thereby improves stability of the composition.
  • Commonly used chelating agents are selected from but not limited to diiospropyl oxalate, disodium EDTA, disodium EDTA-copper, EDTA, diethylene-triamine-pentaacetic acid (DTP A), iminodisuccinic acid (IDS), Eethylenediamine disuccinic acid (EDDS).
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising chelating agent in the range of about 0.005% w/w to about 5 % w/w of the total composition.
  • chelating agent in the range of about 0.005% w/w to about 4 % w/w, more preferably in the range of about 0.005% w/w to about 3 % w/w, more preferably in the range of about 0.005% w/w to about- 2% w/w, more preferably in the range of about 0.005 % w/w to about- 1 % w/w, more preferably in the range of about 0.01% w/w to about-0.5 % w/w, more about preferably 0.05% w/w of the total composition.
  • Emollients are used for protecting, moisturizing, and lubricating the skin.
  • Commonly used emollients are selected from but not limited to petrolatum, lanolin, mineral oil, dimethicone, caprylic triglyceride, Jojoba oil, olive oil, grape seed oil, glyceryl cocoate.
  • the present invention relates to a pharmaceutical composition characterized in that the composition further comprises a suspending agent.
  • Suitable suspending agents are selected from cellulose, cellulose ether like sodium carboxy methyl cellulose is an important cellulose ether, polyacrylic acids, cross-linked polymers of acrylic acid, copolymers of acrylic acid with a hydrophobic monomer, copolymers of carboxylic acid-containing monomers and acrylic esters, cross-linked copolymers of acrylic acid and acrylate esters, natural gums like guar gum, xanthan gum and crystalline long chain acyl derivatives.
  • the long chain acyl derivative is desirably selected from ethylene glycol stearate, alkanolamides of fatty acids having from 16 to 22 carbon atoms and mixtures thereof.
  • Ethylene glycol distearate and polyethylene glycol 3 distearate are preferred long chain acyl derivatives, since these impart pearlescence to the composition.
  • Viscosifier can be added to the current pharmaceutical composition to increase shampoo or lotion viscosity. However, over dosage of these viscosity modifiers may cause negative hair feel, thus it is necessary to optimize its concentration.
  • Viscosifier are selected from but not limited to electrolytes like NH4CI, Sodium Chloride; natural gums selected from gum karaya, tragacanth, alginates; cellulose derivatives selected from hydroxy ethyl cellulose, methyl cellulose; Polyacrylic acid is available commercially as Carbopol selected from but not limited to Carbopol 420, Carbopol 488 or Carbopol 493, CarbopolSilk 100 polymer.
  • Polymers of acrylic acid crosslinked with a polyfunctional agent may also be used; they are available commercially as Carbopol 910, Carbopol 934, Carbopol 941 and Carbopol 980.
  • An example of a suitable copolymer of a carboxylic acid containing monomer and acrylic acid esters is Carbopol 1342.
  • the viscosity of the pharmaceutical composition may range from about 10 cps to about 500 cps or preferably from about 20 cps to about 150 cps.
  • the viscosity can be determined by various known instruments such as a Dynamic stress rheometer or Brookfield viscometer. In a preferred embodiment, the viscosity is determined by a Brookfield cone and plate viscometer by measuring torque transmission through a sample using a rotating spindle at 100 rpm.
  • pH adjuster include, but are not limited to hydrochloric acid, sodium hydroxide, ammonium hydroxide, magnesium hydroxide, sulphuric acid, phosphoric acid, citric acid, malic acid, tartaric acid.
  • the pH adjuster may be used in an amount sufficient to obtain a pH in the range of from about 2 to about 10, preferably from about 5 to about 8, and more preferably from 6 to 7.5.
  • Pharmaceutically suitable acceptable vehicles or solubilizers include, but are not limited to purified water, glycols such as propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters.
  • Purified water may be used in an amount to make the composition 100% by weight of the total composition.
  • the present invention relates to stable shampoo or lotion composition for topical application to a human comprising about 0.05% to about 10% w/w luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients selected from the group consisting of surfactants, preservative, chelating agent, viscosifier, suspending agent, conditioner, emollient and mixture thereof wherein the composition is not free of sodium lauryl ether sulfate.
  • the present invention relates to topical shampoo or lotion composition
  • the present invention relates to topical shampoo or lotion composition
  • a pharmaceutical suspension for topical application to a human in the form of shampoo or lotion comprising about 0.5 % w/w to about 5% w/w luliconazole or its derivative wherein the composition does not contain any additional active agents such as salicylic acid or zinc pyrithione.
  • composition comprising luliconazole which is substantially free of Cocamide diethanolamide.
  • a topical composition comprising luliconazole which is substantially free of sodium cocoyl sarcosinate.
  • a topical composition comprising luliconazole which is substantially free of natural oil and surfactants such as parabens and azolinones.
  • a topical composition comprising luliconazole and pharmaceutically acceptable excipients such as cocamidopropyl betaine, Bis- Aminopropyl Dimethicone and polyethylene glycol ether for beneficial effects.
  • Cocamidopropyl Betaine used as cleansing agent has skin hydrating properties and prevent skin from drying out;
  • Bis- Aminopropyl Dimethicone has strong polarity, can interact with hydroxyl and carboxyl on hair surface, brings very good orientation and absorption property, helps in formation of a smooth and solid film on the hair and polyethylene glycol ether which is compatible with non-ionic, anionic, amphoteric, and cationic surfactants.
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 0.5 % w/w to about 5 % w/w of luliconazole; b) about 5 % w/w to about 30 % w/w of surfactant; c) 0.5% w/w to 3.5 % w/w of conditioner; and d) pharmaceutically acceptable excipients selected from the group consisting of preservative, chelating agent, suspending agent, viscosifier, emollient, pH adjuster, perfume, and mixture thereof. wherein all these percentages being expressed relative to the total weight of the composition.
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 0.5 % w/w to about 5 % w/w of luliconazole; b) about 5 % w/w to 25 % w/w of anionic surfactant selected from alkyl sulfate and alkyl ether sulfate salts such as sodium lauryl ether sulfate (SLES), disodium laureth sulfosuccinate, ammonium laureth sulfate, sodium myreth sulfate, sodium methyl 2- sulfolaurate, disodium 2-sulfolaurate, sodium C14-16 olefin sulfonate, and sodium lauroyl methyl isethionate, sodium lauryl sulfate and mixture thereof; c) about 0.25 % w/w to about 3 % w/w of nononic surfactant selected from
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 0.5 to about 5 % by weight of luliconazole along with surfactants and conditioner; and b) pharmaceutically acceptable excipients includes but not limited to preservatives such as Imidurea (Imidazolidinyl urea), benzoates (such as sodium benzoate, benzoic acid), nitrites (such as sodium nitrite), sulphites (such as sulphur dioxide) or sorbates (such as sodium sorbate, potassium sorbate), chelating agent such as diiospropyl oxalate, disodium EDTA, disodium EDTA-copper, EDTA, diethylene-triamine-pentaacetic acid (DTPA), iminodisuccinic acid (IDS), Ethylenediamine disuccinic acid (EDDS); emollients are choosen from petrol
  • preservatives
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 2 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of Polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53 ; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of diso
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 1 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of Polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53 ; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of diso
  • a topical composition of luliconazole in the form of shampoo or lotion dosage form comprising: a) about 4 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of Polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53 ; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of diso
  • compositions for topical application comprising a) about 2 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of disodium EDTA;
  • compositions for topical application comprising a) about 1 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of polyquaternium-53; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of disodium EDTA;
  • compositions for topical application comprising a) about 4 % w/w of luliconazole; b) about 5% w/w of disodium laureth sulfosuccinate; c) about 2.25 % w/w of sodium lauryl ether sulfate; d) about 0.5 % w/w of polyethylene glycol ether of lauryl alcohol; e) about 0.3 % w/w of cocamidopropyl betaine; f) about 0.1 % w/w of dimethicone and aminopropyldimethicone; g) about 0.5 % w/w of disodium cocoampho diacetate, h) about 0.2 % w/w of Polyquaternium-53; i) about 0.15 w/w of Imidurea; j) about 0.05 % w/w of disodium EDTA;
  • the present invention relates to method of treating dandruff or seborrheic dermatitis , fungal infections associated with Malassezia spp. like pityriasis versicolor as well as dermatophytic infections like tinea capitis, tinea barbae of hairy areas forwashing & treating the skin, hair or the scalp by the application of topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients.
  • the present invention relates to topical composition
  • topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients for the treatment of dandruff or seborrheic dermatitis, fungal infections associated with Malassezia spp. like pityriasis versicolor as well as dermatophytic infections like tinea capitis, tinea barbae of hairy areas for washing & treating the skin, hair or the scalp.
  • the present invention relates to use of topical composition comprising luliconazole or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and pharmaceutically acceptable excipients for the treatment of dandruff or seborrheic dermatitis, fungal infections associated with Malassezia spp. like pityriasis versicolor as well as dermatophytic infections like tinea capitis, tinea barbae of hairy areas for washing & treating the skin, hair or the scalp.
  • a luliconazole shampoo or lotion composition wherein the extent of wrinkling and sloughing (mild) as well as incidences i.e. irritant properties of said shampoo or lotion were comparable with that of the marketed composition.
  • a luliconazole shampoo or lotion composition wherein the said shampoo or lotion is comparable with marketed in terms of skin irritation potential.
  • a luliconazole shampoo or lotion composition wherein the said shampoo or lotion have minimally irritating eye irritation potential and is comparable with marketed shampoo.
  • the invention is directed to methods of using such composition for the treatment of dandruff, Malassezia infections like Pityriasis versicolor, fungal infections like tinea barbae, tinea capitis, etc. It also reduces relapse rates and maintains remissions for Seborrheic dermatitis.
  • the invention provides a process for preparation of pharmaceutical topical composition of luliconazole comprising the steps of:
  • Disodium laureth sulfosuccinate, Laureth-3, purified water were taken and luliconazole API was added in it. Further it was stirred to get uniform dispersion. 2. Purified water was taken and Carbopol silk 100 was added in it. Further it was stirred to get uniform dispersion. 3. Sodium carboxymethylcellulose was added to step-2 and stirred to get uniform dispersion. 4. Step-01 was added to step-03 and stirred to get uniform dispersion.5. Cocoamidopropyl betaine, KF 8020, Merquat 2003PR, MiranolC2M, PEG-7 glyceryl cocoate were added one after another to step-04 and stirred to get uniform dispersion. 6.
  • topical composition was evaluated for quality control tests including but not limited to visual assessment and physiochemical controls such as pH, density, viscosity, surface tension, foam volume, wetting ability, foaming ability, foam stability, hair discoloration or conditioning on swatches of hair.
  • visual assessment and physiochemical controls such as pH, density, viscosity, surface tension, foam volume, wetting ability, foaming ability, foam stability, hair discoloration or conditioning on swatches of hair.
  • active means luliconazole or its salt, solvate, or some additional actives as described herein or combination thereof.
  • derivatives includes all pharmaceutically acceptable salts, solvates, esters, isomers, polymorphs of luliconazole and can be used interchangeably.
  • the invention provides pharmaceutical compositions comprising luliconazole having a dso of from about 11 to about 20 pm, preferably from about 12 to about 16 pm.
  • the particle size can be determined by Malvern analyzer.
  • Foaming height of the composition was determined to ensure the foaming ability.
  • the invention provides pharmaceutical compositions having a foaming height from about 100 to about 300 mm, preferably from about 150 to about 200 pm.
  • the foaming height can be determined by Cylinder shake method.
  • stable topical composition is used to refer to a pharmaceutical composition for application to body surfaces such as the skin, or scalp to treat ailments.
  • the composition may be in any of a range of dosage forms including but not limited to creams, foams, shampoos, powders, gels, lotions, patches, ointments, suspensions and solutions.
  • the composition can be packed in various suitable containers such as tubes, bottle (such as amber color glass, HDPE), pump thereof. All numbers expressing quantities of ingredients used in the specification and claims are to be understood as being modified in all instances by the term “about.” The word “about” means plus or minus 10% of the stated number.
  • substantially free means an amount of a material that is less than 1%, 0.5%, 0.25%, 0.1%, 0.05%, 0.01%, or 0.001% by weight of a composition.
  • Example 1 Topical composition comprising Luliconazole
  • the composition of example 1 can be prepared by using following process:
  • Disodium laureth sulfosuccinate, purified water and luliconazole were charged in a vessel.
  • step-2 Sodium carboxy methyl cellulose was added to step-2 and stirred to get uniform dispersion.
  • Step-01 added to step-03 and stirred to get uniform dispersion.
  • Cocoamidopropyl betaine, KF8020, Merquat 2003PR, Miranol C2M, PEG-7 glyceryl cocoate were added one after another to step-04 and stirred to get uniform dispersion.
  • Step-06 was added to step-05 and stirred to get uniform dispersion.
  • Step-07 and perfume was added to step-07 and stirred to get uniform dispersion.
  • step-09 pH of step-09 was adjusted by using sodium hydroxide solution to 5.00-7.50
  • Example 2 Topical composition comprising Luliconazole
  • composition of example 2 can be prepared by using following process:
  • Disodium laureth sulfosuccinate, purified water and luliconazole were charged in a vessel.
  • step-2 Sodium carboxymethylcellulose was added to step-2 and stirred to get uniform dispersion.
  • Step-01 added to step-03 and stirred to get uniform dispersion.
  • Cocoamidopropyl betaine, KF8020, merquat 2003PR, miranolC2M, PEG-7 glyceryl cocoate were added one after another to step-04 and stirred to get uniform dispersion.
  • Step-06 was added to step-05 and stirred to get uniform dispersion.
  • Step-07 and perfume was added to step-07 and stirred to get uniform dispersion.
  • step-09 pH of step-09 was adjusted using sodium hydroxide solution to 5.00-7.50
  • Disodium laureth sulfosuccinate, Laureth-3, purified water were taken and luliconazole API added in it. Further stirred to get uniform dispersion.
  • step-2 Sodium carboxymethylcellulose added to step-2 and stirred to get uniform dispersion.
  • Step-01 added to step-03 and stirred to get uniform dispersion.
  • Cocoamidopropyl betaine, Dimethicone and aminopropyldimethicone KF8020
  • Polyquaternium-53 Merquat 2003PR
  • Disodium cocoampho diacetate Miranol C2M
  • Glyceryl cocoate added one after another to step-04 and stirred to get uniform dispersion.
  • Step-06 added to step-05 and stirred to get uniform dispersion.
  • compositions of batches 3D, 3E and 3F were subjected to stability studies at different conditions. The results of the same are as follows:
  • Example 4 Evaluation of conditioning was carried out by two methods:
  • Method 4a Sensory evaluation method using compositions containing luliconazole 2%w/w as described in example 3. The objective of this method is to check the softness, smoothness, and manageability of hair against marketed anti dandruff shampoo (the bench mark sample). Brief of protocol for Sensory evaluation of hair swatches by panel:
  • Each hair swatches weight should be 10 gm ( ⁇ 10 %). • Before start the evaluation process, selected swatches washed with 14% active sodium laureth sulfate solution.
  • test sample quantity should be 10% of the hair swatches weight.
  • Method 4b Red 80 dye method using composition containing luliconazole 2%w/w as described in example 3.
  • the objective of this method was to check the conditioning via cationic polymer deposition.
  • test sample was found to be better for softness, smoothness and manageability than marketed anti dandruff shampoo
  • Example 5a Repeated dose 90 days dermal toxicity study in Rodents (Wistar Rats) with 14 days and 28 days recovery period using composition as described in example 3.
  • Exposure contact period 1 hour contact period
  • Example 5b Pilot Study Repeated dose 14 days dermal toxicity study with 7 days of observation in New Zealand White Rabbits among 7 groups using composition as described in example 3.
  • Exposure contact period 1 hour contact period
  • Example 5c Preclinical Repeated dose 90 days dermal toxicity study in New Zealand White Rabbits with 14 days and 28 days recovery period using formulation as described in examples 3.
  • Luliconazole shampoo test sample
  • test sample test item in graded strengths 1%, 2% and 4%
  • placebo group placebo group
  • reference item group placebo group
  • Three reversal groups (Placebo, 4% and reference group)
  • Exposure contact period 1 hour contact period
  • site of application was dabbed with moist cotton soaked in water to mimic the intended mode of administration in humans.
  • the application area was covered with porous gauze and non-irritating tape to prevent the access and ingestion of test item by the animal during the exposure period
  • Duration of Dosing 5 days/week; 1 hour daily for 90 consecutive calendar days
  • test item Luliconazole shampoo (test sample) 2% is comparable with reference marketed shampoo in terms of skin irritation potential. No Observed Adverse Effect Level (NOAEL) of Luliconazole shampoo (test sample) was observed at 4% at 2.5ml/kg body weight; when topically applied to New Zealand white Rabbits for a period of 90 days consecutive days (5 days/week application)
  • NOAEL Adverse Effect Level
  • Example 5d Comparative Evaluation of Eye Irritation / Corrosion potential of Luliconazole shampoo (test sample) with Reference item in New Zealand White Rabbits using formulation as described in examples 3.
  • Test item / reference item was diluted with RO water to achieve 15 % dilution (e. g: 15 mL RO water will be added to 85 mL test item/reference item).
  • Test item/reference item/placebo was instilled on day 1.
  • a volume of 0.1 mL of placebo/test item/reference item was directly instilled into the right eye.
  • test item/reference item was instilled in the conjunctival sac of right eye of each animal after gently pulling the lower lid away from the eyeball. The lids were then gently held together for about one second in order to prevent loss of the material.
  • the eyes of the test animals were washed with saline after 15 minutes following application of the placebo / test item / reference item, if considered appropriate to remove residual placebo / test item / reference item. Eye washing was done slowly, such that pressure of wash solution should not damage the eye.
  • test item and placebo items have minimally irritating eye irritation potential.
  • the Eye Irritation potential of Luliconazole shampoo (test sample) and Placebo is comparable with that of the reference item when tested in undiluted and diluted form (15%) with single dose application in the eyes of the New Zealand white Rabbits.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition topique et pouvant mousser comprenant du luliconazole, et des excipients pharmaceutiquement acceptables sélectionnés dans le groupe constitué par les tensioactifs, les conservateurs, les agents chélatants, les agents améliorant la viscosité, les agents de mise en suspension, les conditionneurs, les émollients, les agents d'ajustement du pH et leurs mélanges. Ladite composition présente divers avantages tels que d'être faiblement irritante pour la peau ou les yeux, produit une excellente mousse crémeuse, possède un effet de soin des cheveux supérieur, et confère une sensation d'hydratation remarquable à la peau. Elle provoque également moins de décoloration des cheveux lorsque comparée à d'autres compositions topiques antifongiques.
PCT/IN2021/050916 2020-09-18 2021-09-17 Composition topique de luliconazole WO2022059027A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202021040485 2020-09-18
IN202021040485 2020-09-18

Publications (1)

Publication Number Publication Date
WO2022059027A1 true WO2022059027A1 (fr) 2022-03-24

Family

ID=80776528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2021/050916 WO2022059027A1 (fr) 2020-09-18 2021-09-17 Composition topique de luliconazole

Country Status (1)

Country Link
WO (1) WO2022059027A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089068A1 (fr) * 2022-10-28 2024-05-02 L'oreal Composition cosmétique comprenant une silicone alpha,omega-bis-amino, une silicone aminée, un tensioactif anionique et un tensioactif amphotère
FR3141344A1 (fr) * 2022-10-28 2024-05-03 L'oreal Composition cosmétique comprenant un tensioactif anionique, un tensioactif amphotère, une silicone alpha-omega bis-aminée et une silicone aminée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093992A1 (fr) * 2009-02-13 2010-08-19 Topica Pharmaceuticals, Inc Formulation antifongique
WO2016015094A1 (fr) * 2014-07-31 2016-02-04 Acrux Dds Pty Ltd Composition topique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010093992A1 (fr) * 2009-02-13 2010-08-19 Topica Pharmaceuticals, Inc Formulation antifongique
WO2016015094A1 (fr) * 2014-07-31 2016-02-04 Acrux Dds Pty Ltd Composition topique

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024089068A1 (fr) * 2022-10-28 2024-05-02 L'oreal Composition cosmétique comprenant une silicone alpha,omega-bis-amino, une silicone aminée, un tensioactif anionique et un tensioactif amphotère
FR3141343A1 (fr) * 2022-10-28 2024-05-03 L'oreal Composition cosmétique comprenant une silicone alpha-omega bis-aminée, une silicone aminée, un tensioactif anionique et un tensioactif amphotère
FR3141344A1 (fr) * 2022-10-28 2024-05-03 L'oreal Composition cosmétique comprenant un tensioactif anionique, un tensioactif amphotère, une silicone alpha-omega bis-aminée et une silicone aminée

Similar Documents

Publication Publication Date Title
US6241971B1 (en) Hair styling compositions comprising mineral salt, lipophilic material, and low levels of surfactant
KR20190037229A (ko) 상승효과적 항진균 조성물 및 그의 방법
US5132107A (en) Two-phase cleansing, conditioning and medicinal treatment shampoo
JP5179879B2 (ja) 組成物
AU2004224326A1 (en) Antifungal nail coat and method of use
WO2022059027A1 (fr) Composition topique de luliconazole
US20110082118A1 (en) Onychomycosis Treatment Delivery System
EP1357884B2 (fr) Composition de traitement des matieres keratiniques comprenant un polymere poly(alkyl) vinyllactame cationique et un agent conditionneur
US20040209954A1 (en) Compositions and methods for treating body malodor and fungal overgrowth in mammals
JPH03275614A (ja) 毛髪化粧料
JP6474963B2 (ja) 洗浄用組成物
JP2002363101A (ja) 外用剤
JP2004352688A (ja) 防腐剤組成物
US7118734B1 (en) Non-aqueous liquid shampoo composition
JP2001031535A (ja) 両性ポリマーと抗フケ剤を含有する化粧品組成物及びそれらの用途
JP2002510292A (ja) 脂漏性皮膚炎、フケ、乾癬及びニキビを治療するジクロロフェニルイミダゾールジオキソランを含有する組成物の使用方法及び該組成物
JP6837470B2 (ja) 洗浄用組成物
FR2646603A1 (fr) Composition nettoyante
US20240173223A1 (en) New topical composition free of sulfate derived surfactants
WO2013138973A1 (fr) Composition d'élimination des pellicules contenant du chlorhydrate de pyridine et de l'uréidohydantoïne
AU2021106154A4 (en) Methods for treating and/or preventing body odour
JP5734998B2 (ja) ベンジルオキシ−エチルアミン誘導体の防腐剤としての使用、防腐方法および組成物
BR112020000120A2 (pt) uso novo
CN101396360B (zh) 一种用于治疗皮肤或头皮浅部真菌感染的药物洗剂及其制备方法
RU2201208C1 (ru) Средство для косметического ухода за проблемной кожей

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21868897

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21868897

Country of ref document: EP

Kind code of ref document: A1